These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 37994574)

  • 61. LncRNA SPRY4-IT1 regulates breast cancer cell stemness through competitively binding miR-6882-3p with TCF7L2.
    Song X; Zhang X; Wang X; Chen L; Jiang L; Zheng A; Zhang M; Zhao L; Wei M
    J Cell Mol Med; 2020 Jan; 24(1):772-784. PubMed ID: 31736268
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A search for reliable molecular markers of prognosis in prostate cancer: a study of 240 cases.
    Tradonsky A; Rubin T; Beck R; Ring B; Seitz R; Mair S
    Am J Clin Pathol; 2012 Jun; 137(6):918-30. PubMed ID: 22586051
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog.
    Paranjape AN; Balaji SA; Mandal T; Krushik EV; Nagaraj P; Mukherjee G; Rangarajan A
    BMC Cancer; 2014 Oct; 14():785. PubMed ID: 25348805
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Selectively Targeting Breast Cancer Stem Cells by 8-Quinolinol and Niclosamide.
    Cámara-Sánchez P; Díaz-Riascos ZV; García-Aranda N; Gener P; Seras-Franzoso J; Giani-Alonso M; Royo M; Vázquez E; Schwartz S; Abasolo I
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233074
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Downregulation of cytokeratin 18 induces cellular partial EMT and stemness through increasing EpCAM expression in breast cancer.
    Shi R; Liu L; Wang F; He Y; Niu Y; Wang C; Zhang X; Zhang X; Zhang H; Chen M; Wang Y
    Cell Signal; 2020 Dec; 76():109810. PubMed ID: 33069797
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Stemness of the hybrid Epithelial/Mesenchymal State in Breast Cancer and Its Association with Poor Survival.
    Grosse-Wilde A; Fouquier d'Hérouël A; McIntosh E; Ertaylan G; Skupin A; Kuestner RE; del Sol A; Walters KA; Huang S
    PLoS One; 2015; 10(5):e0126522. PubMed ID: 26020648
    [TBL] [Abstract][Full Text] [Related]  

  • 67. PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer.
    Santiago-Gómez A; Kedward T; Simões BM; Dragoni I; NicAmhlaoibh R; Trivier E; Sabin V; Gee JM; Sims AH; Howell SJ; Clarke RB
    Cancer Lett; 2019 Aug; 458():66-75. PubMed ID: 31121213
    [TBL] [Abstract][Full Text] [Related]  

  • 68. LGR4 modulates breast cancer initiation, metastasis, and cancer stem cells.
    Yue Z; Yuan Z; Zeng L; Wang Y; Lai L; Li J; Sun P; Xue X; Qi J; Yang Z; Zheng Y; Fang Y; Li D; Siwko S; Li Y; Luo J; Liu M
    FASEB J; 2018 May; 32(5):2422-2437. PubMed ID: 29269400
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Targeting CDK7 reverses tamoxifen resistance through regulating stemness in ER+ breast cancer.
    Attia YM; Salama SA; Shouman SA; Ivan C; Elsayed AM; Amero P; Rodriguez-Aguayo C; Lopez-Berestein G
    Pharmacol Rep; 2022 Apr; 74(2):366-378. PubMed ID: 35000145
    [TBL] [Abstract][Full Text] [Related]  

  • 70. BRD4/nuclear PD-L1/RelB circuit is involved in the stemness of breast cancer cells.
    Kim SL; Choi HS; Lee DS
    Cell Commun Signal; 2023 Nov; 21(1):315. PubMed ID: 37924094
    [TBL] [Abstract][Full Text] [Related]  

  • 71. IL20RA signaling enhances stemness and promotes the formation of an immunosuppressive microenvironment in breast cancer.
    Gao W; Wen H; Liang L; Dong X; Du R; Zhou W; Zhang X; Zhang C; Xiang R; Li N
    Theranostics; 2021; 11(6):2564-2580. PubMed ID: 33456560
    [No Abstract]   [Full Text] [Related]  

  • 72. Emodin reduces Breast Cancer Lung Metastasis by suppressing Macrophage-induced Breast Cancer Cell Epithelial-mesenchymal transition and Cancer Stem Cell formation.
    Liu Q; Hodge J; Wang J; Wang Y; Wang L; Singh U; Li Y; Yao Y; Wang D; Ai W; Nagarkatti P; Chen H; Xu P; Murphy EA; Fan D
    Theranostics; 2020; 10(18):8365-8381. PubMed ID: 32724475
    [TBL] [Abstract][Full Text] [Related]  

  • 73. PIM1 is responsible for IL-6-induced breast cancer cell EMT and stemness via c-myc activation.
    Gao X; Liu X; Lu Y; Wang Y; Cao W; Liu X; Hu H; Wang H
    Breast Cancer; 2019 Sep; 26(5):663-671. PubMed ID: 30989585
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Reprogramming of non-genomic estrogen signaling by the stemness factor SOX2 enhances the tumor-initiating capacity of breast cancer cells.
    Vazquez-Martin A; Cufí S; López-Bonet E; Corominas-Faja B; Cuyàs E; Vellon L; Iglesias JM; Leis O; Martín AG; Menendez JA
    Cell Cycle; 2013 Nov; 12(22):3471-7. PubMed ID: 24107627
    [TBL] [Abstract][Full Text] [Related]  

  • 75. MiR-410 Acts as a Tumor Suppressor in Estrogen Receptor-Positive Breast Cancer Cells by Directly Targeting ERLIN2 via the ERS Pathway.
    Wu H; Li J; Guo E; Luo S; Wang G
    Cell Physiol Biochem; 2018; 48(2):461-474. PubMed ID: 30016800
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Loss of Mel-18 enhances breast cancer stem cell activity and tumorigenicity through activating Notch signaling mediated by the Wnt/TCF pathway.
    Won HY; Lee JY; Shin DH; Park JH; Nam JS; Kim HC; Kong G
    FASEB J; 2012 Dec; 26(12):5002-13. PubMed ID: 22954590
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-κB.
    Wei L; Liu TT; Wang HH; Hong HM; Yu AL; Feng HP; Chang WW
    Breast Cancer Res; 2011 Oct; 13(5):R101. PubMed ID: 22023707
    [TBL] [Abstract][Full Text] [Related]  

  • 78. FZD7 accelerates hepatic metastases in pancreatic cancer by strengthening EMT and stemness associated with TGF-β/SMAD3 signaling.
    Zhang Z; Xu Y
    Mol Med; 2022 Jul; 28(1):82. PubMed ID: 35854234
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Dicer-mediated miR-200b expression contributes to cell migratory/invasive abilities and cancer stem cells properties of breast cancer cells.
    Hsu TW; Chen HA; Liao PH; Su YH; Chiu CF; Huang CY; Lin YJ; Hung CC; Yeh MH; Sung SY; Su CM
    Aging (Albany NY); 2022 Aug; 14(16):6520-6536. PubMed ID: 35951366
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Do Different Stemness Markers Identify Different Pools of Cancer Stem Cells in Malignancies: A Study on ER+ and ER-Breast Cancer Cell Lines.
    Chopra S; Goel S; Thakur B; Bhatia A
    Pathol Oncol Res; 2020 Jan; 26(1):371-378. PubMed ID: 30361903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.